AXA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.38 EUR | -5.10% |
|
-11.51% | -0.37% |
| 06-14 | Countries want natural hazard insurance and insist on: Speed | DP |
| 06-14 | Federal states urge federal government to introduce compulsory natural hazard insurance | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.73 for the current period. Therefore, the company is undervalued.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.37% | 69.29B | - | ||
| +5.50% | 49.46B | B | ||
| +3.66% | 48.75B | B+ | ||
| +17.83% | 44.91B | B+ | ||
| +9.06% | 40.62B | B+ | ||
| +20.40% | 34.09B | B | ||
| -4.92% | 27.56B | B | ||
| -10.60% | 26.6B | B- | ||
| +27.21% | 26.35B | A | ||
| -21.10% | 24.32B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CS Stock
- AXA Stock
- Ratings AXA